Clinical trial
A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
NCT04487080 is registered in ClinicalTrials.gov with Janssen Research & Development, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
- Lead sponsor
- Janssen Research & Development, LLC
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- September 30, 2020
- Completion date
- February 16, 2028
- Enrollment
- 1,074 (actual)
- Sites
- 269
Conditions
As the registry lists them; a condition with its own page is linked.